You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
憂呈第二波新冠肺炎疫情 阿里健康及多隻生物股續受捧屢創上市新高
阿思達克 05-13 11:49
市場憂慮全球出現第二波新冠肺炎疫情,多隻生物相關股繼續受捧,其中藥物生物(02269.HK)及與加拿大合推新冠狀病毒疫苗臨床試驗的康希諾生物(06185.HK)屢創上市新高,最高見138.5元及177.7元,現造136.7元及174.6元,續升5.3%及3.9%;去年5月才以每股4.41元上市的維亞生物(01873.HK)升破去年5月所創上市高位5.45元,最高見5.92元,現造5.7元,續漲12%,成交第二天急增至2,965萬股,涉資1.66億元。此外,藍籌中生製藥(01177.HK)高見12.1元,現造12.02元,回升2.9%。

至於平安好醫生(01833.HK)及阿里健康(00241.HK)高見119.6元及21.5元,現造119.1元及21.35元,續升2.9%及6%,後者第二天創上市新高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account